Molecular testing plays a critical role in AML care, helping doctors identify specific genetic changes that may influence how the leukemia behaves and which treatments may be most effective. Dr. David Sallman explains the different types of testing, what they look for, and why these results are essential to personalizing care.
Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.
Related Resources
Transcript
Katherine Banwell:
Dr. Sallman, can you explain what molecular testing is and why it is critical to AML patient care?
Dr. David Sallman:
Yeah. So, actually, it’s probably the most important part of patient care because, really, it’s no longer that you have a diagnosis of AML. It’s you have a diagnosis of AML with what specific mutation? And so, “molecular” is a broad word. There are now a lot of different tests, and that can actually be quite confusing to patients. It’s actually still quite confusing to, actually, a lot of physician groups as well. So, I would say the key ones that I would say should be uniformly done for all patients would be cytogenetics, which is looking at chromosomes.
I always say you get 23 from Mom, 23 from Dad. If you’re a male, you’re XY. If you’re a female, you’re XX. So, that’s normal, so anything that’s not that is not normal. We can then look for very specific chromosome changes somewhat more rapidly, and that is with FISH tests. And so, FISH is basically staining for a very specific abnormality. And then, most importantly is sort of broad, or what we’d call comprehensive sequencing panels. So, this sequences the genes and looks to say, “Hey, what is different than normal?” And these gene sets can be anywhere between 40 genes to, let’s say, 600 genes based on what lab.
Probably most on average are, let’s say, close to 100 different genes. And then, there are ways to kind of more rapidly detect those. So, sometimes I may want to know, let’s say, two or three different genes as soon as possible because that may personalize your care any more. So, some of these are duplicative. And then, lastly, there are some new technologies, and this is not even universal across comprehensive, let’s say, cancer centers and other groups.
But there are fusion panels that can look for very rare changes, or there are some other sophisticated testing that is continuing to be incorporated. So, this is one of those things that’s going to change day by day.